Gabapentinoids and Risk of Hip Fracture
In this case-case-time-control study of Australian residents hospitalized for hip fracture, gabapentinoid use was associated with an increased risk of hip fractures, especially in patients who were frail or had chronic kidney disease. In addition to the known risk associated with kidney impairment, frailty status may be an important risk factor when considering use of gabapentinoids.
Authors
- Justin P. Turner (ORCID: https://orcid.org/0000-0003-0613-108X)
- Jenni Ilomäki (ORCID: https://orcid.org/0000-0002-0348-9441)
- Miriam T Y Leung (ORCID: https://orcid.org/0000-0002-4259-7058)
- C. Marquina (ORCID: https://orcid.org/0000-0003-0602-492X)
- J. Simon Bell (ORCID: https://orcid.org/0000-0002-6115-2767)
- Tim Tran (ORCID: https://orcid.org/0000-0002-2924-3466)
- Katsiaryna Bykov (ORCID: https://orcid.org/0000-0003-3336-5412)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Eastern Finland (FI)
- Institut Universitaire de Gériatrie de Montréal (CA)
- Austin Health (AU)
- Université Laval (CA)
- Monash University (AU)
- Université de Montréal (CA)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.44488
- Citations
- 21
- Primary Topic
- Cardiac, Anesthesia and Surgical Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 8.44
Funders
- U.S. Department of Health and Human Services
- Amgen
- AstraZeneca
- GlaxoSmithKline
- Australian Government
- National Breast Cancer Foundation
- Society of Hospital Pharmacists of Australia
- Department of Health, State Government of Victoria
- Department of Health and Aged Care, Australian Government
- State Government of Victoria
- Dementia Australia
- Dementia Centre for Research Collaboration
- National Institutes of Health
- Agency for Healthcare Research and Quality
- Medical Research Council
- National Health and Medical Research Council